| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Takeshi Namekawa | Q91163671 |
| P2093 | author name string | Satoshi Inoue | |
| Kazuhiro Ikeda | |||
| Kuniko Horie-Inoue | |||
| P2860 | cites work | Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 |
| A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro | Q24647698 | ||
| Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft | Q43269331 | ||
| A preclinical xenograft model of prostate cancer using human tumors | Q43880974 | ||
| A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens | Q44507804 | ||
| Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. | Q44963439 | ||
| A Nod Scid mouse model to study human prostate cancer | Q45859219 | ||
| Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer | Q46095028 | ||
| Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient | Q46788362 | ||
| Cancer statistics, 2018. | Q47191906 | ||
| Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling | Q47670505 | ||
| US cancer institute to overhaul tumour cell lines | Q47875830 | ||
| Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer | Q47938119 | ||
| The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models. | Q48187480 | ||
| Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells | Q48244745 | ||
| Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. | Q48253273 | ||
| Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer | Q49578235 | ||
| Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy | Q40003248 | ||
| Human urologic cancer cell lines | Q40119643 | ||
| The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines | Q40144292 | ||
| Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. | Q40146469 | ||
| The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment | Q40152977 | ||
| Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. | Q40551887 | ||
| Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line | Q40689267 | ||
| TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. | Q40783686 | ||
| PEAZ-1: a new human prostate neoplastic epithelial cell line | Q40795415 | ||
| Widely used prostate carcinoma cell lines share common origins | Q40812502 | ||
| Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. | Q40916927 | ||
| A new human prostate carcinoma cell line, 22Rv1. | Q40933318 | ||
| Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. | Q40936806 | ||
| Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. | Q41009634 | ||
| The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer. | Q41127809 | ||
| Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft | Q41378102 | ||
| Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines | Q41526936 | ||
| p53 oncogene mutations in three human prostate cancer cell lines | Q41586000 | ||
| Human primary prostate tumor cell line, ALVA‐31: A new model for studying the hormonal regulation of prostate tumor cell growth | Q41587993 | ||
| Establishment and Characterization of a Human Primary Prostatic Adenocarcinoma Cell Line (ND-1) | Q41597850 | ||
| Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process | Q41695916 | ||
| Establishment of new human prostatic cancer cell line (JCA-1). | Q41729073 | ||
| Differential Cytokeratin Expression in Normal, Hyperplastic and Malignant Epithelial Cells From Human Prostate | Q41757486 | ||
| Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system | Q41827081 | ||
| SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer | Q42188512 | ||
| LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. | Q42315779 | ||
| Development and characterization of efficient xenograft models for benign and malignant human prostate tissue | Q42473593 | ||
| Human prostatic adenocarcinoma: Some characteristics of a serially transplantable line in nude mice (PC 82) | Q42801825 | ||
| BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis | Q42802002 | ||
| Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice | Q42808290 | ||
| Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma | Q42815558 | ||
| Expression of HLA-like structures on a permanent human tumor line PC-93. | Q42823457 | ||
| MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms | Q42945633 | ||
| Genome sequencing of normal cells reveals developmental lineages and mutational processes | Q42997512 | ||
| Modeling Development and Disease with Organoids | Q24657457 | ||
| Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer. | Q27853342 | ||
| Organoid development in cancer genome discovery | Q28083032 | ||
| Androgen-independent growth in LNCaP cell lines and steroid uridine diphosphate-glucuronosyltransferase expression | Q28185109 | ||
| NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells | Q28207942 | ||
| The murine autoimmune diabetes model: NOD and related strains | Q28211565 | ||
| Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche | Q28239639 | ||
| A severe combined immunodeficiency mutation in the mouse | Q28274531 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy | Q28298655 | ||
| Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway | Q28480873 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. | Q30307781 | ||
| Androgen-repressed phenotype in human prostate cancer | Q30454285 | ||
| Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms | Q30482634 | ||
| AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression | Q30513836 | ||
| Androgen receptor splice variants determine taxane sensitivity in prostate cancer | Q30577613 | ||
| Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. | Q33222813 | ||
| TACC2 Is an Androgen-Responsive Cell Cycle Regulator Promoting Androgen-Mediated and Castration-Resistant Growth of Prostate Cancer | Q33636574 | ||
| Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines | Q33767962 | ||
| Widespread intraspecies cross-contamination of human tumor cell lines arising at source. | Q33875830 | ||
| Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening | Q33894635 | ||
| VCaP, a cell-based model system of human prostate cancer | Q33943752 | ||
| Use of nude mouse xenograft models in prostate cancer research | Q33947227 | ||
| Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT. | Q33970160 | ||
| Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines | Q33988757 | ||
| Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer | Q34055827 | ||
| HeLa cells 50 years on: the good, the bad and the ugly | Q34127748 | ||
| Establishment and characterization of a human prostatic carcinoma cell line (PC-3) | Q34210915 | ||
| Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model | Q38728309 | ||
| Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells | Q38762346 | ||
| Skp2 is associated with paclitaxel resistance in prostate cancer cells | Q38771323 | ||
| Metabolic heterogeneity signature of primary treatment-naïve prostate cancer | Q38810786 | ||
| Establishment and Characterization of an In Vitro Model of Ovarian Cancer Stem-like Cells with an Enhanced Proliferative Capacity. | Q38811667 | ||
| TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression | Q38832692 | ||
| Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy | Q38844202 | ||
| The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer | Q38914271 | ||
| Organoid culture systems for prostate epithelial and cancer tissue. | Q39035547 | ||
| High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development | Q39041750 | ||
| Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts | Q39085996 | ||
| CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling | Q39122038 | ||
| Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer | Q39156237 | ||
| A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. | Q39181056 | ||
| Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer | Q39236264 | ||
| The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. | Q39246346 | ||
| ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression | Q39420862 | ||
| Identification of docetaxel resistance genes in castration-resistant prostate cancer | Q39452736 | ||
| Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells | Q39564344 | ||
| Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression | Q39605639 | ||
| MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression | Q39712751 | ||
| Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model | Q39741537 | ||
| Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation | Q39749979 | ||
| CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer | Q39804729 | ||
| Isolation of a human prostate carcinoma cell line (DU 145) | Q34255312 | ||
| Molecular characterization of human prostate carcinoma cell lines | Q34266176 | ||
| LNCaP model of human prostatic carcinoma. | Q34271140 | ||
| Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer | Q34340156 | ||
| Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells | Q34340236 | ||
| Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells | Q34416761 | ||
| Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice | Q34420980 | ||
| The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men | Q34443008 | ||
| Organoid models of human and mouse ductal pancreatic cancer | Q34456438 | ||
| Organoid cultures derived from patients with advanced prostate cancer | Q34545103 | ||
| Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient | Q35094512 | ||
| Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment | Q35148340 | ||
| Characterisation and manipulation of docetaxel resistant prostate cancer cell lines | Q35462077 | ||
| A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49 | Q35747677 | ||
| Development of seven new human prostate tumor xenograft models and their histopathological characterization. | Q35782119 | ||
| Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. | Q36005681 | ||
| Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. | Q36005687 | ||
| Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line | Q36079989 | ||
| PC3 is a cell line characteristic of prostatic small cell carcinoma. | Q36185201 | ||
| Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 | ||
| The human PC346 xenograft and cell line panel: a model system for prostate cancer progression | Q36368670 | ||
| PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? | Q36512823 | ||
| Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. | Q36862668 | ||
| BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients | Q36905832 | ||
| Humanized mice for immune system investigation: progress, promise and challenges | Q37111994 | ||
| Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance | Q37145531 | ||
| Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer | Q37352625 | ||
| Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles | Q37444366 | ||
| Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features | Q37582049 | ||
| Ex vivo culture of human prostate tissue and drug development | Q38113460 | ||
| Cancer cell lines for drug discovery and development | Q38203358 | ||
| Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis | Q38250049 | ||
| Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression | Q38328491 | ||
| Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). | Q38603259 | ||
| Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. | Q50577685 | ||
| Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279. | Q50912583 | ||
| Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells | Q50944315 | ||
| Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer | Q51263170 | ||
| Brief report: a bioassay to identify primary human prostate cancer repopulating cells | Q51864082 | ||
| Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer | Q52653620 | ||
| Establishment of a Patient-Derived Tumor Xenograft Model and Application for Precision Cancer Medicine | Q52680757 | ||
| Heterochromatin protein 1α mediates development and aggressiveness of neuroendocrine prostate cancer. | Q52682476 | ||
| Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models | Q52778839 | ||
| Metastatic behavior of human tumor cell lines grown in the nude mouse. | Q52826702 | ||
| LuCaP 35: A new model of prostate cancer progression to androgen independence | Q52832790 | ||
| Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells | Q53143685 | ||
| TabBO: a model reflecting common molecular features of androgen-independent prostate cancer | Q53914758 | ||
| Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. | Q54655043 | ||
| Patient derived organoids to model rare prostate cancer phenotypes. | Q55367999 | ||
| Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. | Q55379433 | ||
| A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer | Q57186003 | ||
| Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer | Q58432602 | ||
| Neuroendocrine differentiation of prostate cancer leads to PSMA suppression | Q58591395 | ||
| Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer | Q58798456 | ||
| Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium | Q63406947 | ||
| Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy | Q64821204 | ||
| Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. | Q64950773 | ||
| Biochemical markers of cultured human prostatic epithelium | Q67343482 | ||
| Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles | Q67946434 | ||
| Identification by C-banding of two human prostate tumour cell lines, 1013L and DU 145 | Q69651417 | ||
| The LNCaP cell line--a new model for studies on human prostatic carcinoma | Q71222674 | ||
| Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice | Q71404712 | ||
| ‘Nude’, a new hairless gene with pleiotropic effects in the mouse | Q72951103 | ||
| Rapid ("warm") autopsy study for procurement of metastatic prostate cancer | Q73605064 | ||
| Karyotypic similarity identified by multiplex-FISH relates four prostate adenocarcinoma cell lines: PC-3, PPC-1, ALVA-31, and ALVA-41 | Q74123190 | ||
| Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells | Q78052193 | ||
| The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft | Q81323685 | ||
| CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers | Q82208584 | ||
| Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer | Q86952613 | ||
| Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer | Q87290450 | ||
| Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models | Q90730820 | ||
| TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis | Q91695777 | ||
| Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer | Q93361861 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| patient | Q181600 | ||
| spheroid | Q208395 | ||
| organoid | Q11293125 | ||
| cell line | Q21014462 | ||
| prostate neoplasm | Q56014511 | ||
| xenograft | Q64148587 | ||
| xenograft model antitumor assay | Q73347741 | ||
| P304 | page(s) | 74 | |
| P577 | publication date | 2019-01-20 | |
| P1433 | published in | Cells | Q27724621 |
| P1476 | title | Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells | |
| P478 | volume | 8 |
| Q92316366 | Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications |
| Q90694324 | Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research |
| Q96304940 | Diagnostic value of microRNA panel in endometrial cancer: A systematic review |
| Q92093077 | Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model |
| Q94465892 | Human Organ-Specific 3D Cancer Models Produced by the Stromal Self-Assembly Method of Tissue Engineering for the Study of Solid Tumors |
| Q101564383 | Patient-derived tumour models for personalized therapeutics in urological cancers |
Search more.